NextCure (NXTC)
(Delayed Data from NSDQ)
$1.60 USD
-0.03 (-1.84%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $1.64 +0.04 (2.50%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
NXTC 1.60 -0.03(-1.84%)
Will NXTC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NXTC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NXTC
Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing
NextCure (NXTC) Down on Shelving Plans to Develop Candidate
NXTC: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy
NextCure, Inc. (NXTC) Moves to Buy: Rationale Behind the Upgrade
Other News for NXTC
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
NextCure (NXTC) Gets a Buy from Piper Sandler
Buy Rating Affirmed on NextCure’s NC410 Promising Clinical Outcomes in MSS-CRC and Ovarian Cancer
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
NextCure presents Phase 1b data on NC410 and pembrolizumab combo at ASCO